005257.KS
Green Cross Holdings Corporation
KSC · Healthcare · Biotechnology · KR
KRW 18,000.00
+1.81%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1963.9B | 1991.3B | 1679.9B | 1626.6B | 1711.3B |
| Cost of Revenue | 1472.2B | 1455.3B | 1198.0B | 1142.0B | 1129.5B |
| Gross Profit | 491.8B | 536.0B | 481.9B | 484.6B | 581.8B |
| Operating Expenses | |||||
| R&D Expense | 113.6B | 152.9B | 166.2B | 173.5B | 191.3B |
| SG&A Expense | 189.2B | 166.3B | 130.1B | 134.4B | 165.1B |
| General & Admin Expense | 28.7B | 37.9B | 33.9B | 34.5B | 44.3B |
| Selling & Marketing Expense | 123.6B | 128.3B | 96.2B | 99.9B | 120.8B |
| Other Expenses | 187.8B | 148.9B | 153.5B | 142.3B | 144.1B |
| Total Operating Expenses | 445.8B | 468.2B | 449.8B | 450.2B | 500.5B |
| Cost and Expenses | 1912.3B | 1922.1B | 1647.8B | 1592.4B | 1630.0B |
| Operating Income (EBIT) | 47.0B | 67.8B | 32.1B | 34.4B | 81.3B |
| Non-Operating | |||||
| Interest Income | 2.2B | 2.8B | 3.3B | 3.2B | 3.5B |
| Interest Expense | 50.9B | 50.3B | 40.4B | 28.5B | 18.4B |
| Net Interest Income | (48.7B) | (47.5B) | (37.1B) | (25.3B) | (14.9B) |
| Other Non-Op Income/Expense | (105.2B) | (104.5B) | (73.2B) | (61.6B) | 4.5B |
| Non-Operating Income (excl Interest) | 92.8B | 54.2B | 32.8B | (5.3B) | (41.0B) |
| EBT (Pre-Tax Income) | (58.2B) | (35.3B) | (41.1B) | (27.1B) | 85.7B |
| Income Tax Expense | 5.3B | (5.6B) | 1.5B | (7.3B) | 16.3B |
| Bottom Line | |||||
| Net Income | (49.9B) | (4.7B) | (26.3B) | (26.6B) | 65.5B |
| Earnings from Cont. Ops | (63.5B) | (29.7B) | (42.6B) | (19.8B) | 69.4B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (49.9B) | (4.7B) | (26.3B) | (26.6B) | 65.5B |
| Per Share | |||||
| Basic EPS | (₩4,372) | (₩410) | (₩2,303) | (₩2,333) | ₩5,735 |
| Diluted EPS | (₩4,372) | (₩410) | (₩2,303) | (₩2,333) | ₩5,735 |
| Revenue Per Share | ₩305,529 | ₩174,459 | ₩147,191 | ₩142,526 | ₩149,944 |
| Shares | |||||
| Basic Shares Outstanding | 6.4M | 11.4M | 11.4M | 11.4M | 11.4M |
| Diluted Shares Outstanding | 6.4M | 11.4M | 11.4M | 11.4M | 11.4M |
| Profitability Metrics | |||||
| EBITDA | 141.3B | 155.5B | 80.4B | 109.8B | 187.0B |
| D&A | 85.8B | 87.7B | 81.0B | 75.9B | 64.8B |
| EBIT | 55.4B | 67.8B | (670.5M) | 33.9B | 122.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026